Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to find out how well patients with a type of cancer called Multiple Myeloma respond to a certain combination of medicines. They will use Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone.
This study wants to find out how well patients with a type of cancer called Multiple Myeloma respond to a certain combination of medicines. They will use Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: